Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

AstraZeneca Announces Approval of Calquence in China

Monday, September 04, 2023

AstraZeneca has announced the approval of Calquence (acalabrutinib), a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor, in China. This approval is for treating adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in China who have received at least one prior treatment. 

This approval from the National Medical Products Administration (NMPA) was granted based on positive results from two clinical trials. The first trial was the ASCEND Phase III trial, which compared Calquence to the investigator's choice of idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) for patients with relapsed or refractory (R/R) CLL. The second trial was an open-label, single-arm Phase I/II trial conducted in China for patients with R/R CLL.

Calquence has already been approved for the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in the United States and Japan. It is also approved for the treatment of CLL in the European Union and in several other countries globally, both in the treatment- naïvoe and relapsed or refractory (R/R) settings. 

Additionally, Calquence is approved in the United States, China, and several other countries for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Many individuals living with chronic lymphocytic leukaemia experience relapse and require additional treatment options to effectively manage the disease. With this approval, patients in China now have access to a well-established treatment that has already demonstrated its effectiveness in numerous patients worldwide.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024